Foshan Radiomedicine

Foshan Ruidiao Pharmaceutical is a leading Chinese biotechnology company focused on the development of innovative radiopharmaceuticals for oncology. Founded in 2012 by Professor Wang Fan of Peking University, the company is a pioneer in the field of nuclear medicine, specifically targeting the integrin αvβ3 receptor. Its flagship product, 99mTc-3PRGD2 (brand name Giluntai), is the world's first broad-spectrum SPECT tumor imaging agent and the first domestically developed Class 1 innovative radiopharmaceutical in China. The company leverages its proprietary "Flexible Spacer Group Modification" platform to enhance the affinity and pharmacokinetics of its molecular probes. Foshan Ruidiao operates as a subsidiary of Beijing Jiluntai Pharmaceutical and maintains a strategic commercialization partnership with Baiyang Pharmaceutical Group to bring its diagnostic and therapeutic solutions to the market.